{"classes":[{"categories":[{"measurements":[{"comment":"The median PFS for group 1 has not been attained.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"The median PFS for group 2 has not been attained","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"33"},{"groupId":"OG001","value":"30"}],"units":"Participants"}],"description":"PFS was defined as the time from registration to progression or death due to any cause.\n\nProgression was defined as any one or more of the following:\n\nAn increase of 25% from lowest confirmed response in:\n\n* Serum M-component (absolute increase \\>= 0.5g/dl)\n* Urine M-component (absolute increase \\>= 200mg/24hour\n* Difference between involved and uninvolved Free Light Chain levels (absolute increase \\>= 10mg/dl)\n* Bone marrow plasma cell percentage (absolute increase of \\>=10%)\n* Definite development of new bone lesion or soft tissue plasmacytomas","dispersionType":"95% Confidence Interval","groups":[{"description":"Bortezomib 1.3mg/m\\^2 by IV days 1, 4, 8 \\& 11\n\nCyclophosphamide 300mg/m\\^2 PO days 1, 8, 15 \\& 22\n\nDexamethasone 40mg PO days 1-4, 9-12, 17-20","id":"OG000","title":"CyBorD (Bortezomib 1.3mg/m^2)"},{"description":"Bortezomib 1.5mg/m\\^2 by IV days 1, 8, 15 \\& 22\n\nCyclophosphamide 300mg/m\\^2 PO days 1, 8, 15 \\& 22\n\nDexamethasone 40mg PO cycle 1-2 days 1-4, 9-12, 17-20, cycle 3 and beyond days 1, 8, 15 \\& 22","id":"OG001","title":"CyBorD (Bortezomib 1.5mg/m^2)"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"up to 5 years","title":"Progression Free Survival (PFS)","type":"SECONDARY","unitOfMeasure":"months"}